VistaGen Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.342; its P/E ratio is ―; VistaGen Therapeutics is scheduled to report earnings on February 18, 2025, and the estimated EPS forecast is $-0.51. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
Income Statement	-
Total Revenue	$ 200.00K	$ 100.00K	$ 197.30K	$ 411.40K	$ 277.70K
Gross Profit	$ 200.00K	$ 100.00K	$ 197.30K	$ 411.40K	$ 277.70K
EBIT	$ -12.95M	$ -10.73M	$ -11.36M	$ -7.88M	$ -6.78M
EBITDA	$ -12.80M	$ -10.58M	$ -11.21M	$ -7.74M	$ -6.64M
Net Income Common Stockholders	$ -12.96M	$ -10.73M	$ -9.52M	$ -6.35M	$ -6.59M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 97.58M	$ 108.36M	$ 119.20M	$ 126.56M	$ 37.61M
Total Assets	$ 102.50M	$ 113.55M	$ 123.65M	$ 131.07M	$ 42.20M
Total Debt	$ 1.79M	$ 1.99M	$ 2.12M	$ 2.25M	$ 2.38M
Net Debt	$ -95.78M	$ -106.37M	$ -117.08M	$ -124.30M	$ -35.23M
Total Liabilities	$ 9.52M	$ 8.74M	$ 9.37M	$ 7.78M	$ 6.55M
Stockholders Equity	$ 92.97M	$ 104.80M	$ 114.30M	$ 123.28M	$ 35.65M
Cash Flow	-
Free Cash Flow	$ -10.95M	$ -10.91M	$ -7.20M	$ -4.57M	$ -6.19M
Operating Cash Flow	$ -10.89M	$ -10.87M	$ -7.20M	$ -4.54M	$ -6.19M
Investing Cash Flow	$ -7.79M	$ -5.47M	$ -28.70K	$ -32.30K	-
Financing Cash Flow	-	$ 88.00K	$ -167.80K	$ 93.52M	$ 34.18M

Currency in USD

VistaGen Therapeutics Earnings and Revenue History

Income Statement >

VistaGen Therapeutics Debt to Assets

Balance Sheet >

VistaGen Therapeutics Cash Flow

Cash Flow >

VistaGen Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing